BEIJING (Reuters) – A Chinese city is offering Sinovac Biotech’s experimental COVID-19 vaccine to key workers and other high-risk groups as part of a national program for about $ 60.
The East City of the Jiaxin Centers for Disease Control and Prevention (CDC) said in a statement to WeChat that two doses of the vaccine candidate, called CoronaVac, would cost 200 yuan ($ 29.75) per dose and that vaccinations for key groups , including medical professionals, have started.
To date, the Chinese authorities have not published details on the prices of potential vaccines against COVID-19. Hundreds of thousands of people received experimental vaccines in the late stages of trials as part of an emergency inoculation program launched in July.
It was not clear whether Jiaxin city prices included subsidies. The city̵
Sinovac did not immediately respond to a request for comment. Its vaccine is in late-stage trials in Brazil, Indonesia and Turkey, and the company said an interim analysis of Phase 3 trial data could appear as early as November.
Bio Farma, a state-owned company in Indonesia that has struck a deal for at least 40 million doses of Sinovac, said this week that the vaccine would cost about 200,000 rupees ($ 13.60) per dose when it becomes available in the Southeast country. Asia.
China has said that while reasonable profits are allowed for companies, COVID-19 vaccines should be priced close to cost.
The Chinese National Pharmaceutical Group (Sinopharm) said in August that a vaccine candidate developed by the department could cost no more than 1,000 yuan ($ 148.80) for two shots. However, a spokesman for China’s National Health Commission said the price would be lower.
($ 1 = 6.7220 Chinese Yuan)
($ 1 = 14 690 0000 rupees)
(Report by Roxanne Liu and Tony Munroe in Beijing. Additional reporting by Kate Lamb; Edited by Sayantani Ghosh and Edwina Gibbs)